Paclitaxel Regulates TRPA1 Function and Expression Through PKA and PKC

• Published in: Neurochemical research 2023-01, Vol.48 (1), p.295-304
• Main Authors: Sánchez, Julio C., Muñoz, Laura V., Galindo-Márquez, María-Leonor, Valencia-Vásquez, Aníbal, García, Andrés M.
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Agonists; Ankyrins; Antineoplastic Agents; Antitumor agents; Biochemistry; Biomedical and Life Sciences; Biomedicine; Calcium (intracellular); Calcium - metabolism; Calcium channels; Calcium currents; Calcium ions; Cell Biology; Chemotherapy; Cytoskeletal Proteins - metabolism; Gene expression; Humans; Kinases; mRNA; Neuroblastoma; Neurochemistry; Neurology; Neurosciences; Original Paper; Oxaliplatin; Paclitaxel; Paclitaxel - pharmacology; Peripheral neuropathy; Phosphatidylinositol 3-Kinases - metabolism; Protein expression; Proteins; RNA, Messenger - metabolism; Toxicity; Transient Receptor Potential Channels - genetics; Transient Receptor Potential Channels - metabolism; Transient receptor potential proteins; TRPA1 Cation Channel - metabolism; Vincristine
• ISSN: 0364-3190; 1573-6903
• DOI: 10.1007/s11064-022-03748-0

Paclitaxel (PTX) is a frequently used anticancer drug that causes peripheral neuropathy. Transient receptor potential ankyrin 1 (TRPA1), a plasma membrane calcium channel, has been associated with PTX toxicity and with other chemotherapy agents such as oxaliplatin and vincristine. However, the effect of PTX on the functional expression and calcium currents of TRPA1 has not been determined. The present study shows the effect of PTX on TRPA1 activity in a neuronal cell line (SH-SY5Y). The effect of PTX on the expression of TRPA1 was assessed through quantitative PCR and Western blot analyses to determine the relative mRNA and protein expression levels. To assess the effect on calcium flux and currents, cells were exposed to PTX; simultaneously, a specific agonist and antagonist of TRPA1 were added to evaluate the differential response in exposed versus control cells. To assess the effect of PKA, PKC and PI3K on PTX-induced TRPA1 increased activity, selective inhibitors were added to these previous experiments. PTX increased the mRNA and protein expression of TRPA1 as well as the TRPA1-mediated Ca 2+ currents and intracellular Ca 2+ concentrations. This effect was dependent on AITC (a selective specific agonist) and was abolished with HC-030031 (a selective specific antagonist). The inhibition of PKA and PKC reduced the effect of PTX on the functional expression of TRPA1, whereas the inhibition of PI3K had no effects. PTX-induced neuropathy involves TRPA1 activity through an increase in functional expression and is regulated by PKA and PKC signaling. These findings support the role of the TRPA1 channel in the mechanisms altered by PTX, which can be involved in the process that lead to chemotherapy-induced neuropathy.